Federal Register of Legislation - Australian Government

Primary content

PB 82 of 2019 Determinations/Health as made
This instrument amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015) to determine the originator brands of a pharmaceutical item for two drugs moving to the Pharmaceutical Benefits Scheme F2 formulary, in addition to some administrative amendments on 1 October 2019.
Administered by: Health
Registered 30 Sep 2019
Tabling HistoryDate
Tabled HR14-Oct-2019
Tabled Senate14-Oct-2019
To be repealed 06 Dec 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 82 of 2019

National Health (Originator Brand) Amendment Determination 2019 (No. 7)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated   30 September 2019

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health



1              Name of Determination

                 (1)     This Determination is the National Health (Originator Brand) Amendment Determination 2019 (No. 7).

(2)     This Determination may also be cited as PB 82 of 2019.

2              Commencement

                This Determination commences on 1 October 2019.

3              Amendments to PB 100 of 2015

                Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).


Schedule 1     Amendments

(section 3)

[1]                   Schedule 1, (table item 88A and 88B)

Repeal the items:

88A

Fluticasone

Flixotide

Flixotide Accuhaler

Flixotide Junior

Flixotide Junior Accuhaler

 

 

88B

Fluticasone with Salmeterol

Seretide Accuhaler 100/50

Seretide Accuhaler 250/50

Seretide Accuhaler 500/50

Seretide MDI 50/25

Seretide MDI 125/25

Seretide MDI 250/25

 

 

Substitute:

88A

Fluticasone propionate

Flixotide

Flixotide Accuhaler

Flixotide Junior

Flixotide Junior Accuhaler

 

 

88B

Fluticasone propionate with salmeterol

Seretide Accuhaler 100/50

Seretide Accuhaler 250/50

Seretide Accuhaler 500/50

Seretide MDI 50/25

Seretide MDI 125/25

Seretide MDI 250/25

 

 

 

[2]                   Schedule 1, (after table item 114A)

Insert:

114B

Insulin glargine

Lantus

Lantus SoloStar

Toujeo SoloStar

 

 

[3]                   Schedule 1, (table item 204 and 204A)

Repeal the items:

204

Risperidone

Risperdal

Risperdal Quicklet

Risperdal Consta

 

 

204A

Rivastigmine

Exelon

Oral

 

Exelon Patch 5

Exelon Patch 10

Exelon Patch 15

Transdermal

 

204A

Rizatriptan

Maxalt

 

 

Substitute:

204

Risperidone

Risperdal

Risperdal Quicklet

Risperdal Consta

 

 

204A

Rituximab

Mabthera

Mabthera SC

 

 

204B

Rivastigmine

 

 

 

 

 

 

 

 

 

 

Exelon

Oral

 

Exelon Patch 5

Exelon Patch 10

Exelon Patch 15

Transdermal

 

204C

Rizatriptan

Maxalt